12:49 AM EDT, 08/31/2026 (MT Newswires) -- OncoZenge (ONCOZ.ST) decided to no longer extend the deadline for the fourth tranche of payment under its 30.2 million-krona investment agreement with Chinese pharmaceutical manufacturing and investment company Sichuan Yangtian Bio-Pharmaceutical. In a same-day release, the Stockholm-listed clinical-stage pharmaceutical company said the investor failed to settle on Aug. 28 the final payment of 10.1 million kronor for 1,562,026 shares. The total allocation for the fourth tranche was 2,334,823 shares, and the company only received 5 million kronor for 772,797 shares. OncoZenge assured that it satisfied its responsibilities under the agreement and that Sichuan Yangtian has no legal basis to withhold payment. The deadline was previously extended in June and July.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.